<DOC>
	<DOC>NCT03098550</DOC>
	<brief_summary>The purpose of this study is to determine whether a combination of nivolumab and daratumumab is safe and effective when treating advanced tumors or tumors that have spread</brief_summary>
	<brief_title>A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread</brief_title>
	<detailed_description />
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Patients with metastatic or advanced solid tumors Women with histologically or cytologically confirmed triple negative breast carcinoma Participants with histologically or cytologically confirmed pancreatic adenocarcinoma Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC) Active brain metastases or leptomeningeal metastases. Any serious or uncontrolled medical disorder Prior malignancy active within the previous 3 years Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-small cell lung cancer (NSCLC)</keyword>
	<keyword>Triple Negative Breast Cancer (TNBC)</keyword>
	<keyword>Pancreatic Cancer (PAC)</keyword>
</DOC>